Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 60Recruiting 22Active not recruiting 13Terminated 12Unknown 4Approved for marketing 2Withdrawn 1Not yet recruiting 1No longer available 1Enrolling by invitation 1

Sponsor Class

OTHER 61OTHER_GOV 6INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

NET 4Endocrine 4CNS 2Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 183Breast Neoplasms 174Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 105Stomach Neoplasms 81Pancreatic Neoplasms 79Lung Neoplasms 79Prostatic Neoplasms 77Melanoma 68Neoplasm Metastasis 67Recurrence 66Leukemia, Myeloid, Acute 66Multiple Myeloma 64Ovarian Neoplasms 62Carcinoma, Hepatocellular 62Lymphoma 61Advanced Solid Tumor 61Advanced Solid Tumors 56Solid Tumor 50Uterine Cervical Neoplasms 48Lymphoma, Non-Hodgkin 48Glioblastoma 44Lymphoma, B-Cell 40Leukemia 39Colonic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Sarcoma 30

Interventions

anlotinib 1amino-acid, glucose, and electrolyte solution 13-Iodobenzylguanidine 1(177)Lu-DOTA-EB-TATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Neuroendocrine Tumors × Clear all
NCT05475210 2024-03-13

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

Molecular Targeting Technologies, Inc.

Phase 1 Unknown
9 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03734913 2020-07-22

A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors

Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Phase 1 Unknown
65 enrolled
CNSDermatologicEndocrineNETThoracic

Carcinoma, Basal Cell, Glioblastoma, Medulloblastoma, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
150 enrolled
EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡